專業研究用書，無法提供教師樣書
內容簡介
Gene therapy has expanded rapidly over the last decade. The number of clinical trials reported by 2001 included 532 protocols and 3436 patients. Phase I trials predominate with 359 trials of 1774 patients versus Phase II (57 trials with 507 patients) and Phase III (3 trials of 251 patients). The disease overwhelmingly targeted by gene therapy is cancer: involving 331 trials with 2361 patients. Despite the somewhat disappointing results of clinical trials to date, gene therapy offers tremendous promise for the future of cancer therapy. The area of gene therapy is vast, and both malignant and nonmalignant cells can be targeted. Suicide Gene Therapy: Methods and Reviews covers gene therapy that targets malignant cells in a treatment that has become known as “suicide gene therapy. ” Basically, this approach uses the transduction of cancer cells with a gene for a foreign enzyme that, when expressed, is able to activate a nontoxic prodrug into a highly cytotoxic drug able to kill the cancer cell population. This is a major area in cancer gene therapy―in 2001 this technique was represented by 52 clinical protocols with a total of 567 patients. Additional trials used multiple gene therapy protocols that also involved suicide gene therapy (83 with 497 patients), indicating that the interest in this area is considerable. Suicide Gene Therapy: Methods and Reviews aims to cover comprehensively, both in theoretical and practical terms, the rapidly evolving area of suicide gene therapy for cancer.
目次
1. Introduction to the background, principles, and state of the art in suicide gene therapy / I. Niculescu-Duvaz and C.J. Springer
2. Introduction to vectors for suicide gene therapy / C.J. Springer
3. Construction of VNP20009: a novel, genetically stable antibiotic-sensitive strain of tumor-targeting Salmonella for parenteral administration in humans / K.B. Low [and others]
4. Nonreplicating DNA viral vectors for suicide gene therapy: the adenoviral vectors / M. Yamamoto and D.T. Curiel
5. Replication-selective oncolytic adenoviruses / G. Hallden [and others]
6. Retroviral vectors for suicide gene therapy / C. Porter
7. Nonviral liposomes / A.D. Miller
8. Peptide- and polymer-based gene delivery vehicles / R. Brokx and J. Gariepy
9. Design of prodrugs for suicide gene therapy / D. Niculescu-Duvaz, I. Niculescu-Duvaz and C.J. Springer
10. Cytochrome p450-based gene therapies for cancer / E.A. Chiocca and D.J. Waxman
11. Tumor sensitization to purine analogs by E. coli PNP / K.V. Curlee, W.B. Parker and E.J. Sorscher
12. Enzyme-prodrug systems: carboxylesterase/CPT-11 / M.K. Danks and P.M. Potter
13. Enzyme-prodrug systems: thymidine phosphorylase/5'-deoxy-5-fluorouridine / A. Evrard [and others]
14. Methods to improve efficacy in suicide gene therapy approaches: targeting prodrug-activating enzymes carboxypeptidase G2 and nitroreductase to different subcellular compartments / S. Schepelmann [and others]
15. Extracellular beta-glucuronidase for gene-directed enzyme-prodrug therapy / S. Brusselbach
16. Enhancement of suicide gene prodrug activation by random mutagenesis / J.E. Kurtz and M.E. Black
17. Combination suicide gene therapy / W. Uckert [and others]
18. Immune response to suicide gene therapy / S. Kuriyama, H. Tsujinoue and H. Yoshiji
19. Targeting cancer with gene therapy using hypoxia as a stimulus / G.U. Dachs, O. Greco and G.M. Tozer
20. Radiation-activated antitumor vectors / S.D. Scott and B. Marples
21. In vitro and in vivo models for evaluation of GDEPT: quantifying bystander killing in cell cultures and tumors / W.R. Wilson [and others]
22. Suicide gene therapy in liver tumors / L.R. Jiao [and others]
23. Clinical trials with GDEPT: cytosine deaminase and 5-fluorocytosine / N.L. Brown and N.R. Lemoine
24. The nitroreductase/CB1954 enzyme-prodrug system / N.K. Green [and others]
25. Side effects of suicide gene therapy / M.M. van der Eb [and others]
26. Antibody-directed enzyme-prodrug therapy / R.B. Pedley [and others]
27. Bioreductive prodrugs for cancer therapy / B. Seddon, L.R. Kelland and P. Workman
